XOMA Royalty Corporation
XOMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeXOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. At a $523.0M market cap, XOMA Royalty Corporation ranks as a small-cap company within healthcare. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
Market Cap
$523.0M
Beta
0.90
P/E (TTM)
26.56
P/E (Fwd)
19.49
EPS (TTM)
$1.57
EPS (Fwd)
$2.14
ROE
34.2%
ROA
1.3%
Cash
$86.1M
Total Debt
$124.7M
Free CF
-$13.1M
52W Change
68.4%
Annual Financials
Cash vs Debt
The company holds $86.1M in cash, though total debt stands at $124.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$13.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 34.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $6.0M (2022) to $11.7M (2025), reflecting a 93% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for XOMA Royalty Corporation and its sector.